Navigation Links
A world free from cancers: Probable, possible, or preposterous?
Date:2/27/2014

e due to innovative cancer treatments since 1990. However, further success in reducing the devastating impacts of cancers and accelerating medical innovation is dependent on developing effective collaborative solutions from an "ecosystem of innovation" bringing together scientists, patients, healthcare providers, private-sector medical innovators, academia, payers and policymakers to find solutions that will save lives from all types of cancers.

"We have made great progress since 1971, when President Nixon declared the war on cancer, in terms of understanding the epidemiology of the disease, improving diagnoses, discovering new treatment paradigms and novel therapeutic approaches to better manage cancers," said Robert Hariri, MD, PhD, chairman, founder and chief scientific officer, Celgene Cellular Therapeutics. "But the progress we've made is not enough. We need to continue the momentum we have started and work together to change the course of human health for patients, healthcare, our economy and future generations."


'/>"/>
Contact: Suzanne Ffolkes
sffolkes@researchamerica.org
571-482-2710
Research!America
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New invasive species breakthrough sparks interest around the world
2. Keeping the world safe for miso soup and Brazilian beans, arctic seed vault welcomes new treasures
3. AGU: Uncovering the secret world of the Plastisphere
4. Worldwide study finds that fertilizer destabilizes grasslands
5. World temperature records available via Google Earth
6. CU-Boulder researchers sequence worlds first butterfly bacteria, find surprises
7. Humans in nature: The world as we find it and the world as we create it
8. Attend the Gut Microbiota for Health World Summit 2014
9. Decoded: DNA of blood-sucking worm that infects worlds poor
10. World Congress on Agroforestry 2014
11. Study shows large carnivore numbers and range declining worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... frequently exposed to heavy traffic pollution or smoke from wood ... University of Melbourne led study has found. The study ... of traffic pollution and wood smoke from heaters on middle-aged ... suffer asthma and were exposed to heavy traffic pollution experienced ...
... needs iron to establish and maintain a biofilm in ... proposed to deprive the bacteria of this necessary element. However, ... published in mBio , the online open-access journal of ... of the two types of iron that are available in ...
... to thousands of species of bacteria collectively called the ... existence. The gastrointestinal (GI) tractand the colon in particularis ... bacterial species. But how do these organisms persist and ... due to foods and fluids moving through it? A ...
Cached Biology News:Traffic pollution and wood smoke increases asthma in adults 2Target 2 forms of iron to control cystic fibrosis lung infection 2A home for the microbiome 2A home for the microbiome 3A home for the microbiome 4
(Date:7/30/2015)... MN (PRWEB) , ... July 31, 2015 , ... Ralco ... Enrichment Center at the Lyon County Fair to be held August 5-9 in Marshall. ... about where their meals come from and how agriculture impacts their daily lives. This ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Focus on ... Supportive ... Companies, Inc. (NYSE: PRX ) today announced its commitment,to ... of Strativa Pharmaceuticals, its proprietary,specialty pharmaceuticals division. Strativa Pharmaceuticals will ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a ... of drugs for the treatment of human ... part of the,restructuring, Idenix has amended the ... Tyzeka(R)/Sebivo(R). Per the amended agreement, Idenix,will discontinue ...
... Settlement, NORCROSS, Ga., Sept. 28 ... leader in providing automated instrument-reagent,systems to the ... and Exchange Commission (SEC) has agreed to ... certain,activities involving the company,s Italian subsidiary. ...
Cached Biology Technology:Introducing Strativa Pharmaceuticals 2Introducing Strativa Pharmaceuticals 3Introducing Strativa Pharmaceuticals 4Introducing Strativa Pharmaceuticals 5Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 2Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 3Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 4Immucor Settles SEC Investigation 2
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
... VIP (6-28) (human, bovine, porcine, ... Peptide (VIP) receptor antagonist. This ... to be twofold more potent ... receptor antagonists. ...
... Invitrogens EvoQuest Services are uniquely ... in the current competitive environment. ... techniques to express, purify, and ... needs: Structure/Function Studies, Activity Assays, ...
Request Info...
Biology Products: